Sodium tetradecyl sulphate sclerotherapy for treating venous malformations of the oral and pharyngeal regions in children

Aim Sclerotherapy is the targeted chemical ablation of varicose veins by intravenous injection of a liquid or foamed sclerosing drug. The treated veins may be intradermal, subcutaneous, and/or transfascial as well as superficial and deep in venous malformations. The aim of this guideline is to give evidence-based recommendations for liquid and foam sclerotherapy. Methods This guideline was drafted on behalf of 23 European Phlebological Societies during a Guideline Conference on 7th–10th May 2012 in Mainz. The conference was organized by the German Society of Phlebology. Results This guideline focuses on the two sclerosing drugs which are licensed in the majority of the European countries, Polidocanol (POL) and Sodium tetradecyl sulphate (STS). Other sclerosants are not discussed in detail. In this paper the results from recent RCTs in sclerotherapy are reviewed.

Download Full-text

Indications, contraindications and performance: European Guidelines for Sclerotherapy in Chronic Venous Disorders

Phlebology The Journal of Venous Disease ◽

10.1177/0268355514528127 ◽

2014 ◽

Vol 29 (1_suppl) ◽

pp. 26-33 ◽

Cited By ~ 18

Author(s):

E Rabe ◽

F Pannier ◽

Keyword(s):

Varicose Veins ◽

German Society ◽

Evidence Based ◽

Venous Malformations ◽

Foam Sclerotherapy ◽

European Guidelines ◽

Chemical Ablation ◽

Sodium Tetradecyl Sulphate ◽

And Performance ◽

Venous Disorders

Aim Sclerotherapy is the targeted chemical ablation of varicose veins by intravenous injection of a liquid or foamed sclerosing drug. The treated veins may be intradermal, subcutaneous, and/or transfascial as well as superficial and deep in venous malformations. The aim of this guideline is to give evidence-based recommendations for liquid and foam sclerotherapy. Methods This guideline was drafted on behalf of 23 European Phlebological Societies during a Guideline Conference on 7th – 10th May 2012 in Mainz. The conference was organized by the German Society of Phlebology. Results This guideline focuses on the two sclerosing drugs which are licensed in the majority of the European countries, Polidocanol (POL) and Sodium tetradecyl sulphate (STS). Other sclerosants are not discussed in detail. In this paper the recommendations concerning indications, contraindications, concentrations, volumes and technique of liquid and foam sclerotherapy of varicose veins and venous malformations are reviewed.

Download Full-text

Percutaneous Sclerotherapy of Venous Malformations of the Head and Neck Using Sodium Tetradecyl Sulphate (Sotradecol)

Scandinavian Journal of Plastic and Reconstructive Surgery and Hand Surgery ◽

10.3109/02844319709085481 ◽

1997 ◽

Vol 31 (2) ◽

pp. 145-150 ◽

Cited By ~ 92

Author(s):

Topi M. J. Siniluoto ◽

Paul A. Svendsen ◽

Gunnar M. Wikholm ◽

Ingemar Fogdestam ◽

Staffan Edström

Keyword(s):

Head And Neck ◽

Venous Malformations ◽

Percutaneous Sclerotherapy ◽

Sodium Tetradecyl Sulphate

Download Full-text

Sodium Tetradecyl Sulphate Direct Intralesional Sclerotherapy of Venous Malformations of the Vulva and Vagina: Report of Five Cases

CardioVascular and Interventional Radiology ◽

10.1007/s00270-010-9916-9 ◽

2010 ◽

Vol 34 (S2) ◽

pp. 228-231 ◽

Cited By ~ 10

Author(s):

Miltiadis Krokidis ◽

Pietro Venetucci ◽

Adam Hatzidakis ◽

Vittorio Iaccarino

Keyword(s):

Venous Malformations ◽

Sodium Tetradecyl Sulphate

Download Full-text

Percutaneous sclerotherapy for spongiform venous malformations – analysis of patient-evaluated outcome and satisfaction

VASA ◽

10.1024/0301-1526/a000650 ◽

2017 ◽

Vol 46 (6) ◽

pp. 477-483

Author(s):

Robert Karl Clemens ◽

Frederic Baumann ◽

Marc Husmann ◽

Thomas Oleg Meier ◽

Christoph Thalhammer ◽

...

Keyword(s):

Retrospective Study ◽

Medical Records ◽

Venous Malformation ◽

Primary Treatment ◽

Venous Malformations ◽

Treated Area ◽

Item Questionnaire ◽

Percutaneous Sclerotherapy ◽

Multiple Treatments ◽

Pain Improvement

Abstract. Background: Congenital venous malformations are frequently treated with sclerotherapy. Primary treatment goal is to control the often size-related symptoms. Functional impairment and aesthetical aspects as well as satisfaction have rarely been evaluated. Patients and methods: Medical records of patients who underwent sclerotherapy of spongiform venous malformations were reviewed and included in this retrospective study. The outcome of sclerotherapy as self-reported by patients was assessed in a 21 item questionnaire. Results: Questionnaires were sent to 166 patients with a total of 327 procedures. Seventy-seven patients (48 %) with a total of 159 procedures (50 %) responded to the survey. Fifty-seven percent of patients were male. The age ranged from 1 to 38.1 years with a median age of 16.4 years. The lower extremities were the most common treated area. Limitations caused by the venous malformation improved in the majority of patients (e.g. pain improvement 87 %, improvement of swelling 83 %) but also worsening of symptoms occurred in a minority of cases. Seventy-seven per cent would undergo sclerotherapy again. Conclusions: Sclerotherapy for treatment of venous malformations results in significant reduction of symptoms. Multiple treatments are often needed, but patients are willing to undergo them.

Download Full-text